SF Healthcare Week: With two commercial products providing cash flow, and more in development, the new CEO of Acadia Pharma is ready to do deals

Jan 14, 2025
1 min read

Updated: Apr 22, 2025

Catherine Owen Adams walks us through the latest on NUPLAZID and DAYBUE, and products in development for Alzheimer's psychosis, Prader-Willi, and essential tremor. Plus, the company's $700M cash balance and deal appetite.

https://vimeo.com/1046832808

Recent Posts

See All

Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads

Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month

San Diego based Replicate Bioscience believes that self-replicating RNA (srRNA) has key advantages over linear or circular RNA. Last year Novo signed on as a partner in obesity and diabetes

SF Healthcare Week: With two commercial products providing cash flow, and more in development, the new CEO of Acadia Pharma is ready to do deals

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight